Evidence map›Paper›PMID 35920592›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain.

Christina M Moloney, Sydney A Labuzan, Julia E Crook, Habeeba Siddiqui, Monica Castanedes-Casey, Christian Lachner, Ronald C Petersen, Ranjan Duara, Neill R Graff-Radford, Dennis W Dickson and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Association of [Neurology · 2026
    Article
  6. Tau PET overlap index correlation with neuropathological findings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Plasma p-tau217 predicting brain-wide tau accumulation in preclinical AD.The journal of prevention of Alzheimer's disease · 2025
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Christina M MoloneyDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Sydney A LabuzanDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Julia E CrookDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
Habeeba SiddiquiDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
Monica Castanedes-CaseyDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Christian LachnerDepartment of Psychiatry, Mayo Clinic, Jacksonville, Florida, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Ranjan DuaraWien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Michelle M MielkeDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0001-7379-2545
Jacksonville College · USMayo Clinic · USMayo Clinic in Florida · USMount Sinai Medical Center · US

Funding

Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI Na Zhao · 2021 to 2026
$42.0M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
Investigating regional and cellular vulnerabilities to tau pathology in young-onset Alzheimer's diseaseR01AG075802 · NIA · MAYO CLINIC JACKSONVILLE · PI BERNARDINO Francesco GHETTI, Lea Tenenholz Grinberg · 2022 to 2026
$15.5M
Clinical Features and Neuropathological Basis of Sleep Wake Behavior in Alzheimer's and PSPR01AG060477 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lea Tenenholz Grinberg, Thomas C Neylan · 2019 to 2026
$8.2M
University of Florida - Mt. Sinai Medical Center AD Research CenterP50AG047266 · NIA · UNIVERSITY OF FLORIDA · PI FEBO, MARCELO · 2015 to 2019
$7.3M
Clinicopathologic and Neuroimaging Differences in Alzheimer's Disease VariantsR01AG054449 · NIA · MAYO CLINIC JACKSONVILLE · PI MURRAY, MELISSA ERIN · 2017 to 2021
$3.9M
"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4M
Tau PET/CT for Early Detection of Alzheimer’s Disease PathologyR01AG073282 · NIA · MAYO CLINIC ROCHESTER · PI LOWE, VAL JOHN, MURRAY, MELISSA ERIN · 2021 to 2025
$2.0M
NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG047266NIA NIH HHS R01 AG054449NIA NIH HHS R01 AG060477NIA NIH HHS R01 AG073282NIA NIH HHS R01 AG075802NIA NIH HHS RF1 AG069052NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG069701
6 · The paper itself

Abstract

introductionAlzheimer's disease (AD) biomarkers are increasingly more reliable in predicting neuropathology. To facilitate interpretation of phosphorylated tau sites as an early fluid biomarker, we sought to characterize which neurofibrillary tangle maturity levels (pretangle, intermediary 1, mature tangle, intermediary 2, and ghost tangle) are recognized.

methodsWe queried the Florida Autopsied Multi-Ethnic (FLAME) cohort for cases ranging from Braak stages I through VI, excluding non-AD neuropathologies and tauopathies. Thioflavin-S staining was compared to immunohistochemical measures of phosphorylated threonine (pT) 181, pT205, pT217, and pT231 in two hippocampal subsectors across n = 24 cases.

resultsEach phosphorylated tau site immunohistochemically labeled early neurofibrillary tangle maturity levels compared to advanced levels recognized by thioflavin-S. Hippocampal burden generally increased with each Braak stage. DISCUSSION: These results provide neurobiologic evidence that these phosphorylated tau fluid biomarker sites are present during early neurofibrillary tangle maturity levels and may explain why these fluid biomarker measures are observed before symptom onset. HIGHLIGHTS: Immunohistochemical evaluation of four phosphorylated tau fluid biomarker sites. Earlier neurofibrillary tangle maturity levels recognized by phosphorylated tau in proline-rich region. Advanced tangle pathology is elevated in the subiculum compared to the cornu ammonis 1 of the hippocampus. Novel semi-quantitative frequency to calculate tangle maturity frequency.

Indexed as

Alzheimer DiseaseBiomarkersBrainNeurofibrillary Tanglestau ProteinsAgedAged, 80 and overAutopsyCohort StudiesFemaleHippocampusHumansMaleMiddle AgedPhosphorylationBiomarkerstau ProteinsAlzheimer's diseasebiomarkerneurofibrillary tangleneuropathologypost mortemtau

Identifiers

PMID35920592
PMCPMC9895127
OpenAlexW4289711479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.